Dermisonics, Inc. (OTCBB: DMSI): is a technology company that holds the intellectual property rights and exclusive marketing rights to an exciting new drug delivery process (the U-Strip^tm) that is capable of administering drug therapies through the skin rather than with hypodermic needles. Dermisonics acquired this technology in 2004 from Encapsulation Systems. Dermisonics is actively engaged in the approval process to commercialize the system for use in delivering insulin, which is used by millions of diabetics daily. In addition, the company is also developing the technology (the U-Wand^tm) to use in conjunction with important new applications in the cosmetics industry, and for wound care (the A-Wand^tm).